Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism

Jeffrey I. Weitz*, Rupert Bauersachs, Jan Beyer-Westendorf, Henri Bounameaux, Timothy A. Brighton, Alexander T. Cohen, Bruce L. Davidson, Gerlind Holberg, Ajay Kakkar, Anthonie W. A. Lensing, Martin Prins, Lloyd Haskell, Bonno van Belien, Peter Verhamme, Philip S. Wells, Paolo Prandoni

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

40 Citations (Web of Science)


Patients with unprovoked venous thromboembolism (VTE) are at high risk for recurrence. Although rivaroxaban is effective for extended VTE treatment at a dose of 20 mg once daily, use of the 10 mg dose may further improve its benefit-to-risk ratio. Low-dose aspirin also reduces rates of recurrent VIE, but has not been compared with anticoagulant therapy. The EINSTEIN CHOICE study is a multicentre, randomised, double-blind, active-controlled, event-driven study comparing the efficacy and safety of two once daily doses of rivaroxaban (20 and 10 mg) with aspirin (100 mg daily) for the prevention of recurrent VTE in patients who completed 6-12 months of anticoagulant therapy for their index acute VIE event. All treatments will be given for 12 months. The primary efficacy objective is to determine whether both doses of rivaroxaban are superior to aspirin for the prevention of symptomatic recurrent VIE, while the principal safety outcome is the incidence of major bleeding. The trial is anticipated to enrol 2,850 patients from 230 sites in 31 countries over a period of 27 months. In conclusion, the EINSTEIN CHOICE study will provide new insights into the optimal antithrombotic strategy for extended VIE treatment by comparing two doses of rivaroxaban with aspirin.
Original languageEnglish
Pages (from-to)645-650
JournalThrombosis and Haemostasis
Issue number3
Publication statusPublished - Sep 2015


  • Venous thrombosis
  • deep-vein thrombosis
  • pulmonary embolism
  • anti-platelet agents
  • prevention

Cite this